Organovo provides business update

Controversial biotech firm Organovo (ONVO) will conduct an online conference for investors on April 10 at 12:00 pm ET. CEO Keith Murphy  will provide an update on the firm's liver tox assay, breast cancer model, R&D and cash position.

Shares have been under pressure since hitting a peak of $13.65 on November 18. Yesterday's close was $7.24.

The company plans to launch its first product, the liver toxicity assay, later this year.

From other sites
Comments (2)
  • 3D Investing
    , contributor
    Comments (1552) | Send Message
    I don't understand the "controversial" part.
    28 Mar 2014, 02:25 PM Reply Like
  • badeconomy
    , contributor
    Comments (251) | Send Message
    whoever is short onvo better run for cover. Onvo will provide information: "the KOL update: guidance on expectations and timelines for key opinion leader (KOL) evaluation of Organovo's 3D Liver tissue".Update on progress of bioprinted breast cancer models: New results from Organovo's bioprinted breast cancer models are expected to be released at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 5-9 in San Diego, CA. Mr. Murphy will review the results on the live investor conference on April 10".


    28 Mar 2014, 03:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs